We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Metal-Enhanced Fluorescence-Based LFI Platform Detects Influenza A Virus in 20 Minutes

By LabMedica International staff writers
Posted on 08 Nov 2023
Print article
Image: A highly sensitive lateral flow immunosensor with mesoporous silica-coated gold nanorods (Photo courtesy of GIST)
Image: A highly sensitive lateral flow immunosensor with mesoporous silica-coated gold nanorods (Photo courtesy of GIST)

Throughout history, as evidenced by the influenza epidemic during World War I, the MERS-CoV outbreak in the 2010s, and the recent COVID-19 pandemic, it has become clear that viral respiratory diseases emerge recurrently. Factors like dense populations, close interactions during travel, and enhanced global connectivity have all contributed to the faster spread of these infections. For the prompt management and containment of such outbreaks, there is a critical need for rapid diagnostic methods that can quickly detect the presence of viruses, which allows for timely isolation and treatment of affected individuals. Fluorescence-based lateral flow immunoassay (LFI) methods have gained popularity as a rapid viral detection mechanism. They rely on the emission of light from specific molecules when they come into contact with viral particles. However, this method has its limitations, particularly related to sensitivity to detect the presence of viruses.

To address the limitations of existing rapid tests, scientists at Gwangju Institute of Science and Technology (GIST, Gwangju, South Korea) have enhanced the capabilities of fluorescence-based LFIs with the introduction of gold nanorod (GNR)-enabled probes. The team engineered probes with a layered core–shell structure called Cy5-mSiO2@GNR, composed of a central GNR core, a mesoporous silica (mSiO2) outer shell, and the fluorescent dye cyanine 5 (Cy5). This novel design counters the usual drawbacks of fluorescence-based LFI such as the quick fading of fluorescent signals and low light emission efficiency through metal-enhanced fluorescence (MEF).

The research team thoroughly analyzed these Cy5-mSiO2@GNR probes, testing their fluorescence in response to different shell thicknesses around the GNR. They identified an optimal thickness of the silica shell at 10.3 nm, setting this as the standard for achieving the most effective enhancement in fluorescence. Utilizing this MEF technique, the researchers successfully demonstrated the use of their optimized probes in an LFI setup for detecting the influenza A virus (IAV).

With the enhanced fluorescence provided by the MEF approach, the LFI system could identify IAV at very low virus concentrations, detecting the virus in as little as 20 minutes. It proved highly specific, able to differentiate IAV even amidst other viruses such as MERS-CoV and SARS-CoV-2, responsible for COVID-19. Furthermore, the system showed exceptional accuracy, over 99%, when identifying IAV in samples taken from patients. This improved Cy5-mSiO2@GNR-based LFI platform presents a significant advancement for point-of-care diagnostics, offering a robust solution for the early and accurate detection of IAV, among other viruses, especially in emergency situations.

“The findings of this research can not only transform rapid testing in healthcare, but its scope can be also extended to other forms of biomolecule diagnostics, with the ultimate goal of improving people’s quality of life,” said Professor Min-Gon Kim from the Department of Chemistry at GIST who led the research.

Related Links:
GIST 

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Unstirred Waterbath
HumAqua 5
New
Ultrasonic Cleaner
UC 300 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.